Seres Therapeutics, Inc. (Nasdaq: MCRB) announced the appointment of Eric D. Shaff as President and Chief Executive Officer.
Mr. Shaff, who is currently Chief Operating and Financial Officer, succeeds Roger J. Pomerantz, M.D. Mr. Shaff has also joined Seres’ Board of Directors and will continue to serve as Seres’ principal financial officer on an interim basis. Dr. Pomerantz will continue as Chairman of Seres’ Board of Directors.
Noubar Afeyan, Ph.D., Lead Director and Co-Founder of Seres Therapeutics and CEO of Flagship Pioneering, commented,
“Eric is an experienced business leader with exceptional strategic and operational acumen, and the Board has great confidence in his ability to successfully lead Seres. We are pleased to continue to work with Roger as he returns to his original role as Board Chair. We thank him for his important contributions to the development and growth of Seres since it spun out from Flagship Pioneering in 2014 and look forward to our additional collaborations.”
Mr. Shaff said:
“Seres continues to be the leader in the research and development of microbiome therapeutics, and I am honored and privileged to lead the Company’s next phase of development. I look forward to executing the most effective path forward for the Company’s strategy, seeking to create value for shareholders, and most importantly, developing meaningful new medicines for patients in need.”
Dr. Pomerantz also commented, saying,
“I am proud of the significant progress that the Seres team has made during the last five years. The Company has developed leading microbiome drug discovery capabilities, unparalleled manufacturing competencies and a number of promising therapeutic candidates for difficult-to-treat diseases. I look forward to Eric’s leadership of the company and a bright future for Seres and its microbiome therapeutics.”
Mr. Shaff has served as Seres’ Chief Financial Officer, Executive Vice President and Treasurer since November 2014, and in January 2018, he was appointed to the additional role of Chief Operating Officer. Mr. Shaff also serves on the Board of Directors for Sigilon Therapeutics and has extensive experience in the biotechnology field, having worked at Momenta Pharmaceuticals and Genzyme Corporation, where he was Vice President of Finance for the Personalized Genetic Health division. Mr. Shaff received his B.A. from the University of Pennsylvania and his MBA from Cornell University.